Best Practice & Research Clinical Haematology
Volume 20, Issue 1 , Pages 85-90 , March 2007

Can reduced-intensity allogeneic transplantation cure older adults with AML?

  • Rainer Storb, MD (Member and Head, Program in Transplantation Biology, Fred Hutchinson Cancer Research Center Professor of Medicine, University of Washington)

      Affiliations

    • Corresponding Author InformationTel.: +1 206 667 4407; Fax: +1 206 667 6124.

References 

  1. Breems DA, Lowenberg B. Autologous stem cell transplantation in the treatment of adults with acute myeloid leukaemia. British Journal of Haematology. 2005;130:825–833
  2. Baron F, Sandmaier BM. Current status of hematopoietic stem cell transplantation after nonmyeloablative conditioning. Current Opinion in Hematology. 2005;12:435–443
  3. Hegenbart U, Niederwieser D, Sandmaier BM, et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. Journal of Clinical Oncology. 2006;24:444–453
  4. de Lima M, Shahjahan M, Alamo A, et al. Allogeneic hematopoietic stem cell transplantation (HSCT) for patients aged 65 years or older with AML and MDS. Blood. 2004;104:632a;(abstract 2301)
  5. Rodriguez R, Parker P, Nademanee A, et al. Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies. Bone Marrow Transplantation. 2004;33:1123–1129
  6. Godwin JE, Kopecky KJ, Head DR, et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). Blood. 1998;91:3607–3615
  7. Leopold LH, Willemze R. The treatment of acute myeloid leukemia in first relapse: a comprehensive review of the literature. Leukemia & Lymphoma. 2002;43:1715–1727
  8. de Witte T, Oosterveld M, Span B, et al. Stem cell transplantation for leukemias following myelodysplastic syndromes or secondary to cytotoxic therapy. Reviews in Clinical and Experimental Hematology. 2002;6:72–85
  9. Scott BL, Sandmaier BM, Storer B, et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia. 2006;20:128–135
  10. Pagel JM, Appelbaum F, Sandmaier BM, et al. 131I-Anti-CD45 antibody plus fludarabine, low-dose total body irradiation and peripheral blood stem cell infusion for elderly patients with Advanced Acute Myeloid Leukemia (AML) or high-risk Myelodysplastic Syndrome (MDS). Blood. 2005;106:119a;(abstract 397)
  11. Mielcarek M, Storer B, Kahl C, et al. Nonmyeloablative and myeloablative hematopoietic cell transplantation for hematologic malignancies: outcomes with HLA-matched unrelated donors compared to HLA-identical sibling donors. Blood. 2005;106:194a;(abstract 658)

PII: S1521-6926(06)00077-6

doi: 10.1016/j.beha.2006.10.008

Best Practice & Research Clinical Haematology
Volume 20, Issue 1 , Pages 85-90 , March 2007

Article Tools

* Image Usage & Resolution